U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H22N4O3
Molecular Weight 378.4252
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FINERENONE

SMILES

CCOc1c2[C@]([H])(c3ccc(cc3OC)C#N)C(=C(C)Nc2c(C)cn1)C(=N)O

InChI

InChIKey=BTBHLEZXCOBLCY-QGZVFWFLSA-N
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H22N4O3
Molecular Weight 378.4252
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

FINERENONE is a potent and selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of FINERENONE were needed to achieve similar cardiorenal protective effects compared to both spironolactone and eplerenone. It is in phase III clinical trials for the treatment of diabetic kidney disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
16.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
2012 Aug
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
2013 Aug
Patents

Sample Use Guides

10 mg or 20 mg once daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:24:29 UTC 2021
Edited
by admin
on Sat Jun 26 15:24:29 UTC 2021
Record UNII
DE2O63YV8R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FINERENONE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
FINERENONE [INN]
Common Name English
1,6-NAPHTHYRIDINE-3-CARBOXAMIDE, 4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-1,4-DIHYDRO-2,8-DIMETHYL-, (4S)-
Systematic Name English
BAY 94-8862
Code English
FINERENONE [USAN]
Common Name English
FINERENONE [WHO-DD]
Common Name English
BAY-94-8862
Code English
(4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
EPA CompTox
1050477-31-0
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
NCI_THESAURUS
C169981
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
CAS
1050477-31-0
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL2181927
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
INN
9634
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
PUBCHEM
60150535
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
FDA UNII
DE2O63YV8R
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
EVMPD
SUB183743
Created by admin on Sat Jun 26 15:24:29 UTC 2021 , Edited by admin on Sat Jun 26 15:24:29 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
MAJOR
EXCRETED UNCHANGED
FECAL
Related Record Type Details
ACTIVE MOIETY